Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
NEW YORK, Jan. 20, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of shareholders of Vital Therapies, Inc. (“Vital Therapies”) (NASDAQ:VTL) who purchased their shares between April 17, 2014 and August 21, 2015.
The complaint alleges that throughout the class period, defendants issued materially false and misleading statements and/or failed to disclose material information regarding the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including (a) the studies’ independent significance; (b) the degree to which the studies were interrelated; and (c) that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial.
On August 21, 2015, after the market closed, Vital Therapies announced that the VTI-208 trial had “failed to meet the primary endpoint of overall survival through at least 91 days…” and that the Company would stop the VTI-210 and VTI-212 clinical trials. Upon this news, Vital Therapies shares plunged 73.4% to close at just $3.65 per share the next trading day.
If you suffered a loss in Vital Therapies you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/vital-therapies.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
